Clinical Research: Disulfiram, a dose escalation study - HIV Cure

Short-term disulfiram administration to reverse latent HIV infection: a dose escalation study Project leader: Dr Julian Elliott Phone: +61 3 9076 6077 Email: julian.elliott@alfred.org.au

Overview

HIV treatment (antiretroviral therapy) is very effective at controlling the HIV virus in most people. However, this treatment is not able to get at dormant, or “sleeping” cells, which are carrying the virus. This is the major barrier to curing HIV and there is now a lot of research being carried out around the world to find ways of “waking up” this dormant HIV.

Recently, a drug that is used in the treatment chronic alcoholism (Disulfiram), has been shown to reactivate latent, or “sleeping” HIV in the laboratory. A small study suggested disulfiram may have the same effect in people.

The aim of this study is to determine whether disulfiram given at different doses is well tolerated by people with HIV and whether it will “wake up” HIV from dormant cells.

Information for Students: Research Opportunities

Please see below for project and contact details.

Please contact Dr Julian Elliott for potential research and study opportunities

Contact person: Dr Julian Elliott

Phone: +61 3 9076 6077

Email: julian.elliott@alfred.org.au

For enquiries related to the clinical trial, please visit the Alfred Clinical Research & Trials web site.

All other student inquiries:

Please contact Brian Price (Business & Community Services Manager)

Email: brian.price@monash.edu

Staff Members:

Collaborators:

Alfred Hospital, Monash University, Burnet Institute - Prof Sharon Lewin

University of California San Francisco (UCSF) - Prof Steve Deeks

Other links:

For enquiries related to the clinical trial, please visit the Alfred Clinical Research & Trials web site.